Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
The functional role of the rs2603751 polymorphism on the expression of Nur77 and its effects related to antipsychotic treatment
EF 2018-19
Résumé
The side effects induced by antipsychotics (AP) are numerous. Currently, no validated biomarker exists that would allow us to identify if an individual is at risk of developing side effects related to the use of AP. Nur77 is a gene that was recently associated with a reduction in the development of tardive dyskinesia (a type of involuntary movement) caused by AP. It is also expressed in the regions of the brain involved with the therapeutic effects of AP and could therefore play a role in the effectiveness of AP in the treatment of schizophrenia. In addition, a polymorphism located on the mRNA of Nur77 is associated with an increase in the risk of developing tardive dyskinesia. This research project therefore aims to study this specific polymorphism in order to observe how it modulates the expression of Nur77 and consequently, how it affects the development of side effects secondary to the use of AP. We will observe the effect of the polymorphism on the expression of Nur77 in cells as well as in mice brains. These results could eventually allow the identification and the validation of a biomarker (the polymorphism of Nur77) in the response to treatment with AP as well as in the vulnerability of developing side effects with the use of AP. To conclude, the knowledge acquired with this study could eventually allow the development of a targeted and individualized pharmacotherapy with less side effects in the treatment of schizophrenia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411255
Name
Majeur Simon
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The functional role of the rs2603751 polymorphism on the expression of Nur77 and its effects related to antipsychotic treatment
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antipsychotics; Biomarker; Nur77; Polymorphism; Schizophrenia; Tardive Dyskinesia
Abstract
The side effects induced by antipsychotics (AP) are numerous. Currently, no validated biomarker exists that would allow us to identify if an individual is at risk of developing side effects related to the use of AP. Nur77 is a gene that was recently associated with a reduction in the development of tardive dyskinesia (a type of involuntary movement) caused by AP. It is also expressed in the regions of the brain involved with the therapeutic effects of AP and could therefore play a role in the effectiveness of AP in the treatment of schizophrenia. In addition, a polymorphism located on the mRNA of Nur77 is associated with an increase in the risk of developing tardive dyskinesia. This research project therefore aims to study this specific polymorphism in order to observe how it modulates the expression of Nur77 and consequently, how it affects the development of side effects secondary to the use of AP. We will observe the effect of the polymorphism on the expression of Nur77 in cells as well as in mice brains. These results could eventually allow the identification and the validation of a biomarker (the polymorphism of Nur77) in the response to treatment with AP as well as in the vulnerability of developing side effects with the use of AP. To conclude, the knowledge acquired with this study could eventually allow the development of a targeted and individualized pharmacotherapy with less side effects in the treatment of schizophrenia.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Majeur, Simon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~